Anthony Sireci

2.4k total citations · 1 hit paper
53 papers, 1.5k citations indexed

About

Anthony Sireci is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Anthony Sireci has authored 53 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 18 papers in Cancer Research and 10 papers in Molecular Biology. Recurrent topics in Anthony Sireci's work include Cancer Genomics and Diagnostics (16 papers), Lung Cancer Treatments and Mutations (14 papers) and Genetic factors in colorectal cancer (6 papers). Anthony Sireci is often cited by papers focused on Cancer Genomics and Diagnostics (16 papers), Lung Cancer Treatments and Mutations (14 papers) and Genetic factors in colorectal cancer (6 papers). Anthony Sireci collaborates with scholars based in United States, Australia and United Kingdom. Anthony Sireci's co-authors include Ahmet Zehir, Susan J. Hsiao, Dara L. Aisner, Ezra Y. Rosen, David M. Hyman, Ryma Benayed, Achim A. Jungbluth, Jaclyn F. Hechtman, James P. Solomon and Kerry Mullaney and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Anthony Sireci

49 papers receiving 1.5k citations

Hit Papers

NTRK fusion detection across multiple assays and 33,997 c... 2019 2026 2021 2023 2019 100 200 300

Peers

Anthony Sireci
Daniel A. Nikcevich United States
Büğe Öz Türkiye
Cheng S. Quah United States
Martin Weger Austria
Ann Bialik United States
MA Goldberg United States
Daniel A. Nikcevich United States
Anthony Sireci
Citations per year, relative to Anthony Sireci Anthony Sireci (= 1×) peers Daniel A. Nikcevich

Countries citing papers authored by Anthony Sireci

Since Specialization
Citations

This map shows the geographic impact of Anthony Sireci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Sireci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Sireci more than expected).

Fields of papers citing papers by Anthony Sireci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Sireci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Sireci. The network helps show where Anthony Sireci may publish in the future.

Co-authorship network of co-authors of Anthony Sireci

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Sireci. A scholar is included among the top collaborators of Anthony Sireci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Sireci. Anthony Sireci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Paweletz, Cloud P., Alison M. Urvalek, Kavita S. Garg, et al.. (2025). Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples. Clinical Cancer Research. 31(12). 2406–2412.
2.
Okusanya, Ólanrewaju O., Gabriela I. Patilea‐Vrana, Anthony Sireci, et al.. (2025). FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers. Clinical Cancer Research. 31(23). 4882–4890.
3.
Loi, Sherene, Stephen Johnston, Carlos L. Arteaga, et al.. (2024). Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).. Journal of Clinical Oncology. 42(17_suppl). LBA507–LBA507. 12 indexed citations
4.
Desmedt, Christine, Nicholas C. Turner, Carlos L. Arteaga, et al.. (2024). 3MO Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE. ESMO Open. 9. 103013–103013. 4 indexed citations
5.
Bhandari, Naleen Raj, Lisa M. Hess, Rohan Parikh, et al.. (2023). Biomarker Testing in Patients Diagnosed With Advanced/Metastatic Medullary Thyroid Cancer in the USA. Personalized Medicine. 20(2). 131–142.
7.
Murray, Suzanne, et al.. (2023). Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study. Thyroid Research. 16(1). 22–22. 2 indexed citations
8.
Sireci, Anthony, Vivek Subbiah, Suzanne Murray, et al.. (2023). Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study. BMC Medical Education. 23(1). 410–410. 1 indexed citations
9.
Hess, Lisa M., Yimei Han, Yajun Emily Zhu, Naleen Raj Bhandari, & Anthony Sireci. (2021). Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. BMC Cancer. 21(1). 28–28. 34 indexed citations
10.
Sireci, Anthony, Deborah Morosini, & S. Michael Rothenberg. (2019). P1.01-101 Efficacy of Immune Checkpoint Inhibition in RET Fusion Positive Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 14(10). S401–S401. 2 indexed citations
11.
Solomon, James P., Irina Linkov, Kerry Mullaney, et al.. (2019). NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Modern Pathology. 33(1). 38–46. 366 indexed citations breakdown →
13.
Hsiao, Susan J., et al.. (2017). The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests. Journal of Molecular Diagnostics. 20(2). 177–183. 8 indexed citations
14.
Sireci, Anthony, Vimla S. Aggarwal, Andrew T. Turk, et al.. (2016). Clinical Genomic Profiling of a Diverse Array of Oncology Specimens at a Large Academic Cancer Center. Journal of Molecular Diagnostics. 19(2). 277–287. 21 indexed citations
15.
Margolskee, Elizabeth, Fei Bao, Roger K. Moreira, et al.. (2016). Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis. Diagnostic Pathology. 11(1). 27–27. 29 indexed citations
16.
Qiu, Wanglong, Andrew T. Turk, Anthony Sireci, et al.. (2015). Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS. Gastroenterology. 150(1). 218–228.e12. 33 indexed citations
17.
Sireci, Anthony, et al.. (2013). Low accuracy of manual white blood cell count in amniotic fluid. Journal of Obstetrics and Gynaecology. 33(4). 364–366. 1 indexed citations
18.
Hussein, Shafinaz, Kamraan Z. Gill, Anthony Sireci, et al.. (2011). Aberrant T‐cell antigen expression in B lymphoblastic leukaemia. British Journal of Haematology. 155(4). 449–456. 24 indexed citations
19.
Sireci, Anthony, John P. Crapanzano, Mahesh Mansukhani, et al.. (2009). Atypical glandular cells (AGC): ThinPrep Imaging System (TIS), manual screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing. Diagnostic Cytopathology. 38(10). 705–709. 5 indexed citations
20.
Cléren, Carine, Lichuan Yang, Beverly Lorenzo, et al.. (2007). Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. Journal of Neurochemistry. 104(6). 1613–1621. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026